The role of positron emission tomography combined with computed tomography in the diagnosis and evaluation of treatment effectiveness of non-small cell lung cancer
- Authors: Meshcheryakova N.A.1, Dolgushin M.B1, Davydov M.M1, Laktionov K.K1, Odzharova A.A1, Nevzorov D.I1, Eremin N.V1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center
- Issue: Vol 21, No 3 (2016)
- Pages: 160-164
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40324
- DOI: https://doi.org/10.18821/1028-9984-2016-21-3-160-164
- ID: 40324
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Nadezhda A. Meshcheryakova
N.N. Blokhin Russian Cancer Research Center
Email: mdnadya@gmail.com
roentgenologist of the Department of positron emission tomography of the Research Institute of Clinical and Experimental Radiology Moscow, 115478, Russian Federation
M. B Dolgushin
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
M. M Davydov
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
K. K Laktionov
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
A. A Odzharova
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
D. I Nevzorov
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
N. V Eremin
N.N. Blokhin Russian Cancer Research CenterMoscow, 115478, Russian Federation
References
- Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 2010; 127: 2893-917.
- Tsim S., O’Dowd C.A., Milroy R., Davidson S. Staging of non-small cell lung cancer (NSCLC): A review. Respir. Med. 2010; 104: 1767-74.
- Zhou Q., Suzuki K., Anami Y., Oh S., Takamochi K. Clinicopathologic features in resected subcentimeter lung cancer e status of lymph node metastases. Interact. Cardiovasc. Thorac. Surg. 2010; 10: 53-7.
- Toloza E.M., Harpole L., McCrory D.C. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003; 123: 137S-46S.
- Shim S.S., Kyung S.L. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005; 236: 1011-9.
- Xing N., Cai Z., Zhao S., Yang Li, Xu B., Wang F. The use of CT perfusion to determine microvessel density in lung cancer: comparison with FDG-PET and pathology. Clin. J. Cancer Res. 2011; 23 (2): 118-22.
- Gallagher F.A. An introduction to functional and molecular imaging with MRI. Clin. Radiol. 2010; 65: 557-66.
- Qi L.P., Zhang X.P., Tang L., Li J., Sun Y.S., Zhu G.Y. Using diffusion-weighted MR imaging for tumor detection in the collapsed lung: a preliminary study. Eur. Radiol. 2009; 9: 333-41.
- Nakayama J., Miyasaka K., Omatsu T., Onodera Y., Terae S., Matsuno Y. et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative assessment with diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient. J. Comput. Assist. Tomogr. 2010; 34 (1): 1-8.
- Ohno Y., Koyama H., Onishi Y., Takenaka D., Nogami M., Yoshikawa T. et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for wholebody diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008; 248: 643-54.
- Chin A.Y., Kyung M.S., Kyung S.L. et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole body MR imaging. Radiology. 2008; 248: 632-42.
- Cronin P., Dwamena B.A., Kelly A.M., Carlos R.C. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology. 2008: 246: 772-82.
- Danielsson R., Baath M., Svensson L. et al. Imaging of regional lymph node metastases with 99mTc-depreotide in patients with lung cancer. Eur. J. Nucl. Med. Mol. Imag. 2005; 32 (8): 925-31.
- Chaitanya R.D. Molecular imaging of pulmonary cancer and inflammation. Proc. Am. Thorac. Soc. 2009; 6: 464-8.
- Yap C.S., Czernin J., Fishbein M.C., Cameron R.B., Schiepers C., Phelp M.E., Webe W.A. Evaluation of thoracic tumors with 18f-fluorothymidine and 18ffluorodeoxyglucose-positron emission tomography. Chest. 2006; 129: 393-401.
- Gould M.K., Kuschner W.G. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with nonsmall-cell lung cancer: a meta- analysis. Ann. Intern. Med. 2003; 139: 879-92.
- Pozo-Rodriguez F., Martin de Nicolas J.L., Sánchez-Nistal M.A., Maldonado A., García de Barajas S., Calero-García R. et al. Accuracy of helical computed tomography and [18F]fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable nonsmall cell lung cancer. J. Clin. Oncol. 2005; 23 (33): 8348-56.
- Sahiner I., Vural G.U. Positron emission tomography/computerized tomography in lung cancer. Quant. Imag. Med. Surg. 2014; 4 (3): 195-206.
- National Cancer Comprehensive Network.www.nccn.org.
- Bakheet S.M., Saleem M., Powe J., Al-Amro A., Larsson S.G., Mahassin Z. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin. Nucl. Med. 2000; 25: 273-8.
- Bradley J., Bae K., Choi N., Forster K., Siegel B.A., Brunetti J.et al. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int. J. Radiat. Oncol. Biol. Phys. 2012; 82: 435-41.
- Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., Owens D.K. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. J.A.M.A. 2001; 285: 914-24.
- Darling G.E., Maziak D.E., Inculet R.I., Gulenchyn K.Y., Driedger A.A., Ung Y.C. et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J. Thorac. Oncol. 2011; 6: 1367-72.
- Schrevens L., Lorent N., Dooms C., Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist. 2004; 9: 633-43.
- Silvestri G.A., Gonzalez A.V., Jantz M.A., Margolis M.L., Gould M.K., Tanoue L.T. et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143: 211S-50S.
- Cho A.R., Lim I., Na I.I., Choe D.H., Park J.Y., Kim B.I. et al. Evaluation of adrenal masses in lung cancer patients using F-18 FDG PET/CT. Nucl. Med. Mol. Imag. 2011; 45: 52-8.
- Hsia T.C., Shen Y.Y., Yen R.F. et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma. 2002; 49: 267-71.
- De Wever W., Bruyeer E., Demaerel P., Wilms G., Coolen J., Verschakelen J. Staging of lung cancer. Do we need a diagnostic CT of the brain after an integrated PET/CT for the detection of brain metastases? JBR-BTR. 2010; 93: 71-6.
- Yi C.A., Shin K.M., Lee K.S., Kim B.T., Kim H., Kwon O.J. et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008; 248: 632-42.
- Stroobants S.G., D’Hoore I., Dooms C. et al. Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer. Clin. Lung Cancer. 2003; 4: 242-7.
- Schmücking M., Baum R.P., Griesinger F. et al. Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res. 2003; 162: 195-202.
- Hicks R.J., Kalff V., MacManus M.P., Ware R.E., Hogg A., McKenzie A.F. et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J. Nucl. Med. 2001; 42: 1596-604.
- Schwenzer N.F., Schraml Ch., Müller M., Brendle C.A., Sauter A., Spengler W. et al. Pulmonary lesion assessment: Comparison of whole-body hybrid MR/PET and PET/CT imaging - pilot study. Radiology. 2012; 264 (2): 551-8.
- Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009; 50 (Suppl. 1): 122S-50S.
- Ding Q., Cheng X., Yang L., Zhang Q., Chen J., Li T., Shi H. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). J. Thorac. Dis. 2014; 6 (6): 677-83.
- van Ruychevelt V., Garcia C., Meert A.P. et al. Positron emission tomography with 18F-FDG and cancer response to chemotherapy. Rev. Mal. Respir. 2011; 28: 618-25.
- Yamamoto Y., Nishiyama Y., Monden T., Sasakawa Y., Ohkawa M., Gotoh M. et al. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imag. 2006; 33: 140-7.
- Decoster L., Schallier D., Everaert H., Nieboer K., Meysman M., Neyns B., De Mey J. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2008; 62: 55-61.
- van Elmpt W., Ollers M., Dingemans A.M., Lambin P., De Ruysscher D. Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J. Nucl. Med. 2012; 53: 1514-20.
- O’Brien M.E., Myerson J.S., Coward J.I., Puglisi M., Trani L., Wotherspoon A. et al. A phase II study of 18F-fluorodeoxygluc ose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks. Eur. J. Cancer. 2012; 48: 68-74.
- Hellwig D., Groschel A., Graeter T.P., Hellwig A.P., Nestle U., Schafers H.J. et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imag. 2006; 33: 13-21.
- Mankoff D.A., Shields A.F., Krohn K.A. PET imaging of cellular proliferation. Radiol. Clin. N. Am. 2005; 43: 153-67.
- Yamamoto Y., Nishiyama Y., Kimura N., Ishi-kawa S., Okuda M., Bandoh S. et al. Comparison of (18) F-FLT PET and (18) F-FDG PET for preoperative staging in non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imag. 2008; 35: 236-45.
- Yap C.S., Czernin J., Fishbein M.C., Cameron R.B., Schiepers C., Phelps M.E., Weber W.A. Evaluation of thoracic tumors with 18F-fluorothymidine and 18Ffluorodeoxyglucose-positron emission tomography. Chest. 2006; 129: 393-401.
- KyoichiKaira, Noboru Oriuchi, Noriaki Sunaga, Tamotsu Ishizuka, Kimihiro Shimizu, Nobuyuki Yamamoto. Review article. A systematic review of PET and biology in lung cancer. Am. J. Transl. Res. 2011; 3 (4): 383-91.
- Everitt S.J., Ball D.L., Hicks R.J., Callahan J., Plumridge N., Collins M. et al. Differential 18F-FDG and 18F-FLT uptake on serial PET/CT imaging before and during definitive chemoradiation for NSCLC. J. Nucl. Med. 2014. 55 (7): 1069-74.
- O’Donoghue J.A., Zanzonico P., Pugachev A., Wen B., Smith-Jones P., Cai S. et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu (II)-diacetyl-bis (N4-methylthiosemi-carbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiogra-phy, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int. J. Radiat. Oncol. Biol. Phys. 2005; 61: 1493-502.
- Evans S.M., Koch C.J. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003; 195: 1-16.
- Dehdashti F., Mintun M.A., Lewis J.S., Bradley J., Govindan R., Laforest R. et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur. J. Nucl. Med. Mol. Imag. 2003; 30: 844-50.
- Wan W., Guo N., Pan D., Yu C., Weng Y., Luo S. et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J. Nucl. Med. 2013; 54: 691-8.